MedPath

Effect of Dietary Phospholipids on Atopic Dermatitis

Not Applicable
Completed
Conditions
Dermatitis, Atopic
Interventions
Dietary Supplement: milk phospholipid
Dietary Supplement: diary product
Registration Number
NCT01326520
Lead Sponsor
University of Jena
Brief Summary

The aim of the study is to investigate the influence of a milk phospholipid enriched dairy product on subjects with atopic dermatitis determining parameters of the immune status, the plasma lipid profile and the skin texture.

Detailed Description

Based on the facts, that on the one hand milk phospholipids are characterized by a high sphingolipid content and on the other hand a disturbed sphingolipid metabolism in the epidermis of patients with atopic dermatitis was verified, a double blinded, controlled, randomized, cross-over study with a daily supplementation of 3 g milk phospholipids to subjects with a mild to moderate atopic dermatitis will be conducted.

Forty patients will be randomized between two groups of each 20 patients. After an individual checkup and a run-in period of 2 weeks, the one group will receive the phospholipid enriched dairy product and the second group will be given a placebo dairy product over two month. A wash out-period of 4 weeks will follow, and the patients will consume the contrary dairy products over two month after a 2-week run-in period again.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
39
Inclusion Criteria
  • mild to moderate atopic dermatitis (SCORAD < 30)
  • age: 18 - 60 years
Exclusion Criteria
  • intolerance against milk proteins
  • systemic medication with corticosteroids or antihistamines
  • immune mediated disease
  • atherosclerosis
  • hyperlipidaemia
  • diabetes mellitus
  • angina pectoris
  • adipositas
  • pregnancy and breast feeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Phospholipid enriched dairy productmilk phospholipid-
dairy productdiary product-
Primary Outcome Measures
NameTimeMethod
Change in skin texture from baseline and in comparison with placeboafter 0,2,10,16, and 24 weeks

SCORAD Index

Secondary Outcome Measures
NameTimeMethod
Immune statusafter 0,2,10,16, and 24 weeks

total IgE, specific IgE, sE selectin, Interferon-gamma, Tumor necrosis factor-alpha, Interleukin 4, 12, 16, 31

Lipid statusafter 0,2,10,16, and 24 weeks

Blood lipids (Total cholesterol, LDL cholesterol, HDL cholesterol, triacyl glycerdies, fatty acids, phospholipids)

Trial Locations

Locations (1)

Friedrich Schiller University Jena, Department of Nutritonional Physiology

🇩🇪

Jena, Thuringia, Germany

© Copyright 2025. All Rights Reserved by MedPath